About GEn1E Lifesciences

GEn1E Lifesciences is a multitarget platform for novel, next generation immunomodulators for rare and inflammatory diseases. By applying machine learning to its “platform in a mechanism” model, GEn1E has developed a pipeline of 21+ novel compounds. Their lead compound is a purpose-built therapy for acute respiratory distress syndrome (ARDS), a serious respiratory condition with no approved therapeutic treatments and high mortality rate.